Showing 1551-1560 of 2314 results for "".
- Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of GAhttps://modernod.com/news/aviceda-announces-dosing-of-first-patient-with-avd-104-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-ga/2481647/Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its phase 2 SIGLEC trial by Ashkan Abbey, MD, of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong preclinical in
- BioTissue’s Sharing Miracles Partners with Dakota Lions Sight & Health to Expand Birth Tissue Donationhttps://modernod.com/news/biotissues-sharing-miracles-partners-with-dakota-lions-sight-health-to-expand-birth-tissue-donation/2481642/To enable more mothers to donate birth tissue used in the restoration of sight and health, BioTissue’s Sharing Miracles program has announced a partnership with Dakota Lions Sight & Health. The collaboration will bring the Dakota Lions birth tissue donation program to additional hospita
- Precision Eye Therapy for Dogs Ready for Human Clinical Developmenthttps://modernod.com/news/precision-eye-therapy-for-dogs-ready-for-human-clinical-development/2481576/A successful gene therapy trialed at Michigan State University in dogs with an inherited eye disease is ready to be developed for clinical use in human patients with retinitis pigmentosa, according to a university news release. Simon Petersen-Jones, professor and Donald R. Myers and Wil
- Startup Vedere Bio II Shuts Down After Preclinical Studies Fall Shorthttps://modernod.com/news/startup-vedere-bio-ii-shuts-down-after-preclinical-studies-fall-short/2481512/About 2 years after its launch, gene therapy start-up Vedere Bio II is shutting down. The decision comes after preclinical studies did not meet targets. The announcement was made from the company’s chairman Kevin Bitterman and CEO Cyrus Mozayeni. “We had a bold mission, to d
- Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of RPhttps://modernod.com/news/endogena-therapeutics-completes-dose-escalation-in-the-phase-12a-clinical-trial-of-ea-2353-for-the-treatment-of-retinitis-pigmentosa/2481511/Endogena Therapeutics announced that the dose-escalation stage of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP) has been successfully completed. No clinically relevant or dose-limiting adverse events were identified after repeated intravitreal injections. Given the positive sa
- FDA Approves Twice-Daily Dosing of Vuity for Adults with Presbyopiahttps://modernod.com/news/fda-approves-twice-daily-dosing-of-vuity-for-adults-with-presbyopia/2481502/The FDA has approved a twice-daily dosing option of Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia, according to AbbVie, the parent company of Allergan. A second dose (one additional drop in each eye) may be administered 3-6 hours after the fi
- OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet AMDhttps://modernod.com/news/olix-pharmaceuticals-doses-first-patient-in-clinical-trial-for-rnai-therapeutic-olx10212-for-dry-and-wet-amd/2481494/OliX Pharmaceuticals announced that the first patient has been successfully dosed in a phase 1 clinical trial (
- Real-World Experience Shows Tepezza was Effective in Treating People with Dysthyroid Optic Neuropathy (DON)https://modernod.com/news/real-world-experience-shows-tepezza-was-effective-in-treating-people-with-dysthyroid-optic-neuropathy-don/2481465/Horizon Therapeutics announced results of an analysis of real-world treatment with Tepezza in Thyroid Eye Disease (TED) patients with DON, the majority of whom had not previously responded to other treatments. DON is a complication of TED characterized by thyroid-related impairment of visual
- Frontera Therapeutics Doses First Patient in a Trial of FT-002 Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosahttps://modernod.com/news/frontera-therapeutics-doses-first-patient-in-a-trial-of-ft-002-gene-therapy-for-the-treatment-of-x-linked-retinitis-pigmentosa/2481415/Frontera Therapeutics announced that it has dosed the first patient in a clinical trial of its gene therapy product, FT-002, which is being studied for the treatment of X-linked retinitis pigmentosa (XLRP) and is Frontera’s third gene therapy product candidate to enter the clinic.
- Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defectshttps://modernod.com/news/trefoil-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-tthx1114-for-treatment-of-corneal-epithelial-defects/2481356/Trefoil Therapeutics announced dosing of the first patient in its phase 1 safety study evaluating TTHX1114 as a topical eye drop formulation designed to reduce the duration and impact of corneal epithelial defects. The phase 1 study is designed to assess t